Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase IIIa Randomized, Controlled Study to Assess the Immunogenicity of GlaxoSmithKline (GSK) Biologicals' 10-valent Pneumococcal Conjugate Vaccine, When Administered as a 3-dose Primary Immunization Course Before 6 Months of Age

NCT00307541 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT00307541
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00307541 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase IIIa Randomized, Controlled Study to Assess the Immunogenicity of GlaxoSmithKline (GSK) Biologicals' 10-valent Pneumococcal Conjugate Vaccine, When Administered as a 3-dose Primary Immunization Course Before 6 Months of Age
Lead sponsor
GlaxoSmithKline
Phase
Phase 3
Overall status
Completed
Start date
October 27, 2005
Completion date
April 7, 2006
Enrollment
120
Sites
32

Conditions

As the registry lists them; a condition with its own page is linked.

infections, streptococcal, streptococcus pneumoniae vaccines